Functional analysis further revealed that KRAS mutations led to upregulation of WNT, MAPK, and IL-6/JAK/STAT signaling pathways, which are known to facilitate cancer cell proliferation, growth, and invasion, resulting in more aggressive disease and reduced treatment response35–37. This evidence concerns the gene IL6 and cancer.